This hands-on workshop introduces Mastra.ai, a TypeScript framework that streamlines the development of agentic AI systems compared to traditional approaches using LangChain and vector databases. Participants will learn to build structured AI workflows with composable tools and reliable control, enabling them to create internal AI assistants that can handle requests like data cleaning, email drafting, and document summarization with minimal code. The session covers Mastra installation, running a local MCP s ...

来源丨 白鲸出海（ID：baijingapp） 作者丨 张凯然 编辑丨 殷观晓 图源丨Midjourney 以下文章来源于白鲸出海 ，作者白鲸小编 从数据上看，Starla 的起量的时间点大约是在 6 月 10 日，6 月 21 日达到下载量巅峰，日下载量峰 值达 11 万，基本集中在美国市场，Astra 整体稍晚几天，大约从 14 日开始起量，日下载量在 23 日突破了 10 万。今天，两款产品虽掉出了榜单前 10，但下载量仍在高位。 白鲸出海 . 除了下载表现不错，Starla 也拿下了用户的真金白银，从 6 月 10 日起收入暴涨，截止 6 月 28 日 已经达到了 218 万美金。Astra 则在这波增长之前，每月大概也能有 30 万美金入账，6 月流水小幅 提升至 40 万美金左右。 白鲸出海，泛互联网出海服务平台，白鲸专注于具备互联网属性的行业、公司、产品和服务的出海，包 括应用、游戏、电商、区块链、智能手机及硬件、旅游、网络文学、影视、动漫、教育、体育和金融 等。 6 月 17 日，一款 AI 占星产品 Starla-Call the Universe 进入了 iOS 美国下载总榜前 10，当笔 ...

本文来自微信公众号：白鲸出海 （ID：baijingapp），作者：张凯然，编辑：殷观晓，头图来自：AI生成 6月17日，一款AI占星产品Starla-Call the Universe进入了iOS美国下载总榜前10，当笔者以为这又是一个昙花一现的产品时，它不仅能够持续坚守榜单Top 10长达半个月，而且到了6月24日，另一款产品Astra-Life Advice也进入了美榜前10，两款同类产品相继进入Top 10，并双双持续在榜超1周的时间。 从数据上看，Starla的起量的时间点大约是在6月10日，6月21日达到下载量巅峰，日下载量峰值达11万，基本集中在美国市场，Astra整体稍晚几天，大约 从14日开始起量，日下载量在23日突破了10万。今天，两款产品虽掉出了榜单前10，但下载量仍在高位。 Starla和Astra近30天收入｜图片来源：点点数据 除了下载表现不错，Starla也拿下了用户的真金白银，从6月10日起收入暴涨，截止6月28日已经达到了218万美金。Astra则在这波增长之前，每月大概也能 有30万美金入账，6月流水小幅提升至40万美金左右。 一、用AI改造星座App，体验一般 从笔者的体 ...

Investor Presentation May 2025 .头. Astrana Health Forward Looking Statements This presentation contains for ward-lookingstatements within the meacing of the Pivate Securities Lifyation Reform Att of 1985Section 274 of the Securities Aut and Section looding statements in blude any vatatements about the Company is business, financial conditibin, operating results, plans, odpectives, expectations and intentions, expansi market, our ability to successful Jr corrupted and realize the benefits of anticipated a ap ...

机器之心报道 机器之心编辑部 一块经过 shunt mod 改装的华硕 ROG Astral LC RTX 5090 的性能，超越了售价 10,000 美元的 RTX Pro 6000。 「Shunt Mod」 是一种硬件级别的、具有高风险性的电路改装方法，主要用于绕过电子设备（特别是高性能显卡和主板）内置的功耗（功 率）和电流限制。 这项惊人的成果来自硬件改装大师 Der8auer（本名 Roman Hartung）。 一种提高硬件功率限制的改装 前面我们已经谈到，Der8auer 使用了 Shunt mod 分流改装。但其并不是万能的，可能对 GPU 的寿命造成危险。如果操作不当，你高价买的 GPU 可能会慢慢降级， 或者非常快速地损坏。 除了对 PCB 改装本身的担忧外，Der8auer 表示 16 针电源连接器在达到 800W 时所承受的应变可能会变得更高，从而更加危险。 那什么是理想的 Shunt mod 呢？ Der8auer 解释道，他特意等了一段时间，从而获得一款配备高效一体式液冷（AiO）的显卡后才进行这次分流器改装实验，因为液冷方案能更好地应对更高的功 耗。根据他的测试，华硕 ROG As ...

机器之心发布 图 1: Astra 模型概述 二、Astra 双模型架构揭秘，赋能机器人高效导航 机器之心编辑部 在当今科技飞速发展的时代，机器人在各个领域的应用越来越广泛，从工业生产到日常生活，都能看到它们的身影。然而，现代机器人导航系统在多样化和复杂的室内环境中 面临着诸多挑战，传统方法的局限性愈发明显。 一、传统导航瓶颈凸显，Astra 应势而生 在复杂的真实世界中，移动机器人想要安全可靠地行走，必须解决三大挑战：我要去哪？我在哪？我要怎么去？这正是目标定位、自我定位与路径规划三大导航核心问题。目 标定位时，在某些应用中，目标可能通过自然语言或目标图像提示指定，这就需要系统理解提示并在地图中定位目标；自我定位要求机器人在地图中确定自身位置，尤其是在 像仓库这样高度重复且缺乏全局地标的复杂场景中，传统导航系统常依赖人工地标，如 QR 码；路径规划又分为全局规划和局部规划，全局规划根据机器人位姿和目标位姿生 成粗略路线，局部规划则负责在避开障碍物的同时到达全局路径上的中间路点。 为解决这些任务，传统导航系统通常由多个模块组成，包含多个小模型或基于规则的系统。近年来，基础模型的出现促使人们将小模型集成到更大的 ...

I wanted to try on the new XR glasses. They looked incredible based on project Astra. Do you think glasses are kind of the best the optimal form factor for this personal artificial intelligence interaction.Glasses, they're really powerful because they're just like you're going about your day-to-day life. You're just interacting with things. It is in your line of sight and maybe can even talk to you more privately, right.It's incredible. Uh you just mentioned memory. I just had this amazing experience with A ...

Biodesix (BDSX) FY Conference Summary Company Overview - Biodesix is a leading diagnostics company focused on lung health, aiming to transform patient care through personalized diagnostics that are timely and accessible [4][3] - The company generates revenue from two segments: lung diagnostic tests and biopharmaceutical services [4][5] Financial Performance - Biodesix reported $18 million in revenue for Q1, representing a 21% year-over-year growth [51] - Revenue from lung diagnostic tests was $16.3 million, growing 18%, while development services saw a significant growth of 61% [51] - The company maintains industry-leading gross margins at just under 80% and expects to reach adjusted EBITDA breakeven by the end of the year [7][52] Product Portfolio - Biodesix has five Medicare-covered lung diagnostic tests, with three having advanced diagnostic laboratory status [6][7] - The company is expanding into digital diagnostics to complement its proteomic and genomic solutions [6] - The lung diagnostic portfolio includes tests for lung nodule risk assessment and treatment guidance [11][37] Market Opportunity - Lung cancer remains the deadliest cancer in the U.S., with one in five cancer-related deaths attributed to it [10][11] - The company aims to address the significant gap in early diagnosis and treatment selection for lung cancer patients [11][12] Clinical Studies and Data Development - Biodesix is conducting two key studies: ALTITUDE (a randomized prospective study) and CLARIFY (a retrospective chart review study) to demonstrate the efficacy and utility of its tests [24][25] - The company has published over 300 clinical publications and presentations, focusing on health economics and outcomes data [6][23] Sales Strategy - Biodesix plans to expand its sales force to 95 representatives by year-end, focusing on pulmonology [6] - The company is also targeting primary care physicians to improve patient referrals to pulmonologists, addressing the issue that many patients do not see specialists [32][35] Future Developments - The company is working on four tests in development, including a risk of recurrence test that combines proteomic and genomic data [42][43] - Biodesix is exploring expanded indications for its Veristrat test in other disease states, including prostate cancer [45][46] - The company is also venturing into digital diagnostics to enhance patient identification and improve test outcomes [47][48] Conclusion - Biodesix is positioned for transformative growth in 2025, with a strong focus on data development and expanding its product pipeline [53][54] - The company emphasizes the importance of its pulmonology-focused sales force and the potential impact of its diagnostic solutions on patient outcomes [54]

导读： 赛默飞世尔在ASMS2025推出Orbitrap Astral Zoom和OrbitrapExcedion Pro质谱仪，助力生物过程解密与疾病研究突破。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 美国当地时间2025年6月2日，赛默飞世尔科技（NYSE: TMO）于第73届美国质谱年会（ASMS）重磅推出两款革新性质谱仪： Thermo Scientific™ Orbitrap™ As tral™ Zoom 质谱系统和Thermo Scientific™ Orbitrap™ Excedion™ Pro 质 谱 系 统 。 这 两 款仪 器 以 卓 越 的分析性能与速度，致力于解密复杂生物过程，推动阿尔茨海默症、癌症等重大疾病研究的突破，为精准医学与生物制药开发提供全新引擎。 Orbit r ap Ast r a l Zo om 创新技术亮点： 超高速扫描：35%的速度提升加速海量数据采集 极致通量：40%的效率跃升支持大规模样本筛查 智能多重检测：50%的多重能力扩展实现单次实验多维分析 应用拓展： 深度蛋白质组学分析、痕量 ...

Summary of Arvinas ASCO Data Conference Call Company and Industry Overview - **Company**: Arvinas - **Industry**: Biotechnology, specifically focused on cancer treatment, particularly for ER positive HER2 negative breast cancer Key Points and Arguments 1. **Phase III VERITAGE II Study Results**: The conference discussed the results of the Phase III VERITAGE II study of beftegastrant (Vepdeg) as a monotherapy for ER positive HER2 negative breast cancer, highlighting its potential as a best-in-class second-line therapy for ESR1 mutant breast cancer [2][4][5] 2. **Mechanism of Action**: Vepdeg works by directly inducing degradation of the estrogen receptor via the proteasome, which differentiates it from other ER-targeting therapies [4][5] 3. **Unmet Medical Need**: There is a significant unmet need for effective treatments in the second-line setting for patients with ESR1 mutant metastatic breast cancer, with approximately 20,000 new patients diagnosed each year in the U.S. [6][7][19] 4. **Efficacy Data**: In the VERITAGE II trial, Vepdeg achieved a median progression-free survival (PFS) of 5.0 months compared to 2.1 months for fulvestrant, representing a statistically significant improvement of 2.9 months [12][22] 5. **Comparison with Other Treatments**: Vepdeg demonstrated a better PFS compared to other recent SERDs, such as elacestrant and molesterine, which showed improvements of 1.9 months and 1.7 months, respectively, over fulvestrant [7][8] 6. **Safety Profile**: Vepdeg was generally well tolerated, with low rates of treatment-emergent adverse events, particularly gastrointestinal issues, which are common with oral SERDs [17][19] 7. **Regulatory Plans**: Arvinas is on track to submit a new drug application (NDA) to the FDA in the coming weeks, indicating confidence in the product's potential [20][24] Additional Important Content 1. **Patient Population**: The trial included a representative real-world patient population, with all patients having received prior CDK4/6 inhibitors and endocrine therapy [12][22] 2. **Market Research Insights**: Clinicians remain underwhelmed by current monotherapy options, indicating a strong market opportunity for Vepdeg [19] 3. **Future Development**: Discussions with Pfizer regarding the commercialization strategy are ongoing, especially in light of the recent trial results and the potential for Vepdeg to be a leading treatment option [40][45] 4. **QT Prolongation Concerns**: The study noted a mild QT prolongation effect of 11.1 milliseconds, which was not considered a significant concern by investigators [70][71] 5. **Patient Reported Outcomes**: Future presentations will include patient-reported outcome data, which showed statistically significant improvements in quality of life and pain interference [20] This summary encapsulates the critical insights from the Arvinas ASCO Data Conference Call, focusing on the company's advancements in cancer treatment and the promising data surrounding Vepdeg.